



RICARDO CAMPELLO

Partner

+55 21 3550 3759
+55 21 99806 5413
ricardo.campello@lickslegal.com

PRACTICE AREAS

- Contracts
- Food & Drug Law
- Government Contracts & Public Procurements
- Litigation
- Patents
- Regulatory Law
- Trade Secrets & Regulatory
- Intellectual Property
- Unfair Competition

LANGUAGES

- Portuguese
- English

BIOGRAPHY

Ricardo Campello is an Attorney at Law at Licks Attorney's Rio de Janeiro office since 2011. Mr. Campello has a wide-ranging practice in Food and Drug Law for companies in the biotechnology, pharmaceutical, medical device and cosmetic industries. Mr. Campello assists his clients in their day-to-day business operations, as well as on specific regulatory issues in the fields of clinical trials ethic review process, GMP inspections, application for marketing approval, post-marketing amendments, product liability, labeling and advertising requirements.

In the recent years, aside his regulatory practice, Ricardo has been deeply involved with the implementation of Federal Government's Industrial Policy for the pharmaceutical sector by signing tech transfer and drug supply agreements with government-owned pharmaceutical industries (Partnership for Productive Development – PDP agreements).

REPRESENTATIVE CASES

- Represented a Japanese pharmaceutical company in the leading case discussing the requirements for signing and implementing contracts related to the PDP program of the Ministry of Health;
- Represented a client on a class action filed by the municipality seeking to force the 40 defendants to sell their drugs with the mandatory discount established by the Brazilian legislation for sales to the public administration;
- Assisted a Korean pharmaceutical company on all steps of the negotiations of the 2015 round of the PDP program before the Ministry of Health;
- Represented a US biopharmaceutical company on the first class action in Brazil discussing whether the sponsor of a clinical trial is bound to supply, without any time limitation, the drug tested in the clinical trials to an individual after their completion, as well as whether the sponsor is liable to reimburse the government for the costs involving said supply.



PROFESSIONAL HIGHLIGHTS

- Análise Advocacia – Pharmaceutical (2023, 2022, 2021);
- Análise Advocacia – Rio de Janeiro (2022);
- The Legal 500 – Life Sciences Practice (2022).

AFFILIATIONS

- Brazilian Bar Association – Rio de Janeiro and São Paulo Sections (OAB/RJ and OAB/SP).

EDUCATION

- LL.M, Government Procurement, George Washington University (GWU), 2020;
- LL.M, Public Law and Regulation, Getúlio Vargas Foundation (FGV), 2012;
- LL.B, Federal University of Rio de Janeiro (UFRJ), 2009.

PUBLICATIONS

- [Mais um passo para a retomada das PDPs: a minuta de norma resolve os erros do passado?](#), JOTA, 2023;
- [Another step towards the return of PDPs: does the draft new regulation solve past mistakes?](#) Lexology, 2023;
- [Prescribing cannabis products only as a last resort](#), Chambers and Partners, 2023;
- [A prescrição de produtos de Cannabis só como última alternativa](#), JOTA, 2023;
- [Governo relança PDPs, preocupação com propriedade intelectual na indústria farmacêutica](#), Decisor Brasil, 2023;
- [Brazilian government resurrects its Partnership for Productive Development \(PDP\) program. A new threat to pharma IP rights?](#), Kluwer Patent Blog;
- [Mudanças na regulamentação da CGU da Lei Anticorrupção não garantem imparcialidade](#), Estadão, 2023;
- [Brazilian Anti-Corruption Act: sanctions record vs. difficulty in defending companies](#), 2023;
- [How does CGU interpret the Brazilian Anticorruption Statute terms](#), 2023;
- [A Amazônia em destaque: Uma oportunidade para a biotecnologia no Brasil](#), Decisor Brasil, 2023;
- [Lei Anticorrupção: recorde de sanções vs. dificuldade na defesa das empresas](#), Conjur, 2023;
- [Como a CGU interpreta prazos da Lei Anticorrupção](#), Valor Econômico, 2023;
- [Skinny label in Brazil: drug authority seeking to implement new regulations](#), Kluwer Patent Blog, 2023;
- [The Amazon in the Limelight: An Opportunity for Biotech in Brazil](#), Genetic Engineering & Biotechnology News, 2023;
- [O Brasil está de volta: será que as PDPs também?](#), JOTA, 2023;
- [Indústria de genéricos usa prática ilegal no Brasil para alterar bulas e infringir patentes](#), Migalhas, 2022;
- [A dinâmica de reembolso de hospitais por planos de saúde](#), JOTA, 2022;
- [Opening the Brazilian radiopharmaceutical market: opportunities brought by Constitutional Amendment #118/2022](#), JOTA, 2022;
- [Abertura do mercado brasileiro de radiofármacos com a EC 118/2022](#), JOTA, 2022;
- [Impressões sobre as mudanças trazidas pela lei 14.307/22 na lei dos planos de saúde](#), Migalhas, 2022;

- [O vai e volta da Anvisa na transparência de pedidos de registro de medicamentos](#), JOTA, 2022;
- [Consensualidade na Anvisa: um diagnóstico a partir de dados da pandemia](#), JOTA, 2021;
- [Entre avanços e preconceitos: as restrições à publicidade de produtos de cannabis](#), Migalhas, 2021;
- [As restrições à publicidade de produtos de cannabis](#), Migalhas, 2021;
- [O desafio dos biossimilares e a postura do Ministério da Saúde no Brasil](#), Migalhas, 2021.
- [The price regulation in Brazil: Roche faces IP rights abuse claims](#), Lifesciences Intellectual Property Review, 2016;
- [Partnering for Profit](#), Lifesciences Intellectual Property Review, 2015.